The vaccine market is becoming an increasingly strategic component of preventive healthcare as governments, healthcare organizations, and pharmaceutical companies continue to prioritize immunization, outbreak preparedness, and long-term disease prevention. The market was valued at USD 72.8 billion in 2025 and is estimated to reach USD 78.1 billion in 2026, before expanding to USD 115.8 billion by 2033, registering a CAGR of 5.8% from 2026 to 2033.

Download a free sample copy of the Vaccine market report to understand detailed coverage and inclusions in the final report

Market Growth and Key Dynamics

Vaccine demand is being supported by the continued prevalence of infectious diseases, expanding adult and geriatric immunization programs, and recovery of routine vaccination coverage following pandemic-related disruptions. Public immunization programs remain an important foundation for demand, while increasing investment in research and development is supporting new vaccine platforms and broader disease coverage.

The rising prevalence of infectious diseases and stronger pandemic preparedness efforts are major growth drivers. Outbreaks involving COVID-19, influenza, dengue, RSV, measles, and other viral infections have reinforced the importance of vaccine development and manufacturing capacity. Governments, healthcare organizations, and pharmaceutical companies are investing in immunization programs and infrastructure to strengthen preparedness and reduce future outbreak risks.

Preventive healthcare awareness and expanding adult vaccination programs are also strengthening demand. The WHO and Gavi reported in April 2026 that more than 100 million vaccine doses had been delivered to 18.3 million children across 36 countries under “The Big Catch-Up” initiative since 2023.

Technology and Product Innovation

Technology is reshaping vaccine development, with mRNA, recombinant, and viral vector platforms supporting faster development and broader disease protection. Platform-based approaches can enable greater flexibility in antigen selection and support the development of combination vaccines.

The expansion of mRNA technology beyond COVID-19 is particularly significant. Pfizer and BioNTech initiated Phase III clinical trials for an mRNA-based influenza vaccine in September 2022, while the WHO reported in May 2025 that its mRNA Technology Transfer Programme had expanded to 15 global partners. These developments support greater manufacturing capacity and technology transfer.

Next-generation technologies are also creating opportunities across influenza, RSV, HIV, cancer immunotherapy, and other infectious diseases. The cancer vaccines segment is projected to grow at the fastest CAGR of 9.10% during the forecast period, reflecting growing attention to therapeutic vaccines and precision medicine.

Market Segmentation and Leading Categories

Viral vaccines remained the leading indication segment, accounting for 61.17% of revenue in 2025. Continued national immunization programs, regulatory support, and ongoing investment in viral vaccine platforms are supporting its position.

By type, subunit vaccines accounted for the largest revenue share of 30.72% in 2025 and are expected to register the fastest CAGR of 7.67%. Their reliability, safety profile, and scalable manufacturing characteristics continue to support institutional adoption.

Parenteral administration dominated the market with an 84.80% revenue share in 2025. However, nasal vaccines are projected to register the fastest CAGR of 6.44%, driven by interest in needle-free delivery, mucosal immunity, and patient convenience.

The adult segment represented the largest age-group share at 56.65% in 2025 and is expected to grow at the fastest CAGR of 6.63%. Expanding vaccination recommendations for influenza, shingles, pneumococcal disease, and COVID-19 are supporting sustained adult immunization demand.

Hospital and retail pharmacies represented 56.36% of revenue in 2025 and are also expected to register the fastest CAGR of 6.76%. Their accessibility, operating hours, established infrastructure, and growing role in adult vaccination are strengthening their position as key vaccination access points.

Regional Market Outlook

North America accounted for the largest market share, representing 39.80% of global revenue in 2025. Strong public funding, advanced healthcare infrastructure, high adult immunization uptake, and continued investment in vaccine innovation support its market position.

Asia Pacific is expected to record a significant CAGR of 7.5% during the forecast period. Population growth, expanding healthcare access, increased public health investment, and strengthening domestic manufacturing capabilities are supporting the region's growth momentum.

Challenges and Future Opportunities

High vaccine development and distribution costs remain a significant market restraint. Research, clinical trials, regulatory approvals, manufacturing, cold-chain infrastructure, and quality-control requirements can create substantial financial burdens. Smaller biotechnology companies may also face challenges related to funding and commercialization.

At the same time, advancements in mRNA and next-generation platforms present substantial opportunities. Growing demand for combination vaccines, wider adult immunization, improved coverage, strategic collaborations, and government funding are creating avenues for long-term expansion.

FAQs

How big is the vaccine market?

The vaccine market was valued at USD 72.8 billion in 2025, is estimated at USD 78.1 billion in 2026, and is projected to reach USD 115.8 billion by 2033, growing at a CAGR of 5.8% from 2026 to 2033.

What trends are shaping the vaccine market?

Major trends include expanding adult immunization, growing pandemic preparedness, mRNA and next-generation vaccine technologies, broader disease coverage, combination vaccines, and increasing investment in manufacturing and supply resilience.

Key Vaccine Companies:

Serum Institute of India Pvt. Ltd.
Seqirus
Sanofi
Merck & Co., Inc.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Why Next-Generation Platforms Could Redefine Vaccine Market Growth

The global vaccine market size was valued at USD 72.8 billion in 2025 and is projected to grow from USD 78.1 billion in 2026 to USD 115.8 billion by 2033